



## Interim Report January – September 2008

### **71 percent increase of net sales and strongly improved operating profit during the first 9 months of this year**

- **Net sales** for the interim period amounted to 52.2 million SEK (30.6) and for the third quarter to 16.5 million SEK (10.4).
- **EBIT** for the interim period amounted to 7.8 million SEK (3.9) and for the third quarter to 2.9 million SEK (2.6).
- **Profit after tax** for the interim period amounted to 6.6 million SEK (4.8) and for the third quarter to 2.5 million SEK (2.9).
- **Earnings per share** for the interim period amounted to 0.71 SEK (0.51) and for the third quarter to 0.26 SEK (0.31).
- Successful common cold study gives opportunity for product launches within the immune area during 2009.
- Three new agreements have been signed during the third quarter for the distribution of a dietary supplement based on Lp299v in Poland, Argentina as well as eight countries in the Balkan and Central European regions.
- Continued large raw material deliveries to Kraft Foods and increased distribution for NextFoods *GoodBelly* in the US.
- After the period's end, Probi's partner Institut Rosell signed an agreement for the sale of a dietary supplement based on Probi's Lp299v in Spain.

### **CEO's comments:**

"The most important accomplishment for Probi in the third quarter is that we are now able to offer a world class immune product. We now have the opportunity to launch our first new probiotic product since the company was founded, and widen the company's product portfolio to a very large and profitable market that is worth 40 billion SEK globally. This is a great break through for Probi. We continue to increase our turnover and create profit in a turbulent time. Especially pleasing is that we are increasing our margins," says Michael Oredsson, CEO of Probi.

### **For further information, contact:**

Michael Oredsson, CEO, Probi, phone: +46 (0)46 286 89 23 or +46(0)707 18 89 30, e-mail: [michael.oredsson@probi.se](mailto:michael.oredsson@probi.se)

Distributed Oct. 28th, 2008, 11:00 (CET)

### **About Probi**

Probi is a leading player in the field of probiotic research and development of effective and well-documented probiotics. The research areas are: stomach and gastrointestinal tracts, immune defense, metabolic disorders as well as stress and recovery. Probi's customers are leading companies within the business areas Functional Food and Dietary Supplements. The company's total operating income was 44.7 million SEK 2007, consisting mostly of royalty revenues. Probi's shares are listed on the Nordic List of the Stockholm Stock Exchange, Small Cap and has approximately 4.000 shareholders. Visit [www.probi.com](http://www.probi.com)

